Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
Hematology Disease Topics & Pathways:
Anemias, Adult, Diseases, Non-Biological, Therapies, Biological Processes, erythropoiesis, Study Population, Clinically relevant
Methods: While based on the same trial design, the studies were performed by different investigators and companies in differing global regions. Patients with baseline Hb <10 g/dL and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 not on dialysis were randomized to roxadustat or placebo (pbo) in the OLYMPUS (North and South America, Asia-Pacific and Europe; N=2781, 1:1 ratio to pbo), ALPS (South America, Europe and South Africa; N=597, 2:1 ratio to pbo), and ANDES (North and South America, Asia-Pacific and Australasia; N=922; 2:1 ratio to pbo) double-blind randomized controlled trials (RCTs). Oral iron was administered unrestricted; intravenous (IV) iron was limited to rescue therapy in those with low iron stores and poor treatment response. The primary endpoint was the mean change in Hb from baseline to the average over Weeks 28–52.
Results: Significant (P<0.001) and consistent improvements in Hb were observed with roxadustat vs pbo across all studies (Figure) and were maintained over time. IV iron rescue therapy use was lower with roxadustat vs pbo (Figure). Overall safety of roxadustat was comparable with pbo and consistent with the CKD patient population.
Conclusion: Roxadustat consistently improved anemia in patients with NDD-CKD across the global roxadustat clinical program, in studies performed by different investigators and companies and in varying global locations.
Disclosures: Pecoits-Filho: Fresenius Medical Care: Research Funding; Akebia: Consultancy; AstraZeneca: Consultancy. Hardy: AstraZeneca: Current Employment, Current equity holder in private company. Yu: FibroGen Inc.: Current Employment, Current equity holder in private company. Fishbane: Cara Therapeutics: Research Funding; Corvidia Therapeutics: Research Funding; Ardelyx: Research Funding; AstraZeneca: Consultancy, Research Funding; MegaPro Biomedical Co Ltd: Research Funding; Akebia Inc.: Research Funding.
See more of: Oral and Poster Abstracts